Quest Diagnostics Inc. (DGX)
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Continue to Retain DGX Stock in Your Portfolio?
Quest Diagnostics continues to stay on investors' radars due to its robust Advanced Diagnostics offerings and strength in acquisitions.
Quest Diagnostics: A Leader But Waiting For Better Price
Quest Diagnostics excels in scale, scope, and service quality, leveraging automation and distribution to reduce costs and offer comprehensive test menus. Despite its strengths, I recommend waiting to buy DGX at $140 for a 15% IRR, as the current valuation is high. Valuation analysis shows DGX trading at a premium; base case IRR is 8.46%, below my 15% threshold, warranting a Hold rating.
Quest Diagnostics Incorporated (DGX) Q1 2025 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q1 2025 Results Conference Call April 22, 2025 8:30 AM ET Company Participants Shawn Bevec - Vice President of Investor Relations Jim Davis - Chairman, Chief Executive Officer, President Sam Samad - Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Kevin Caliendo - UBS Patrick Donnelly - Citi Elizabeth Anderson - Evercore ISI Michael Cherny - Leerink Partners Pito Chickering - Deutsche Bank Noah Kava - Jefferies David Westenberg - Piper Sandler Michael Ryskin - Bank of America Andrew Brackmann - William Blair Jack Meehan - Nephron Research Erin Wright - Morgan Stanley Operator Welcome to the Quest Diagnostics First Quarter 2025 Conference Call. At the request of the company, this call is being recorded.
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up
DGX delivers solid top-line growth in the first quarter of 2025.
Quest Diagnostics (DGX) Q1 Earnings and Revenues Beat Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.04 per share a year ago.
Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy?
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings
DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics and benefits from acquisitions.
DGX Stock Gains Following the Launch of New AD-Detect Blood Test
Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET imaging and cerebral spinal fluid testing.
Is Quest Diagnostics Stock Worth Holding Onto Right Now?
Strong momentum in Advanced Diagnostics and strategic acquisitions continues to attract investors to DGX.
DGX Stock Set to Benefit From New Google Cloud Partnership
Quest Diagnostics teams up with Google Cloud to streamline data and personalize customer experiences using gen AI.
